DAGCO Inc. Cuts Stock Position in Merck & Co., Inc. (NYSE:MRK)


Share on StockTwits

DAGCO Inc. cut its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 6.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,133 shares of the company’s stock after selling 2,443 shares during the period. Merck & Co., Inc. comprises about 1.3% of DAGCO Inc.’s portfolio, making the stock its 24th biggest position. DAGCO Inc.’s holdings in Merck & Co., Inc. were worth $2,554,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Raab & Moskowitz Asset Management LLC increased its stake in shares of Merck & Co., Inc. by 2.5% during the first quarter. Raab & Moskowitz Asset Management LLC now owns 47,640 shares of the company’s stock worth $3,672,000 after buying an additional 1,148 shares during the period. Park Avenue Securities LLC increased its stake in shares of Merck & Co., Inc. by 19.5% during the first quarter. Park Avenue Securities LLC now owns 83,607 shares of the company’s stock worth $6,445,000 after buying an additional 13,625 shares during the period. JJJ Advisors Inc. increased its stake in shares of Merck & Co., Inc. by 18.0% during the first quarter. JJJ Advisors Inc. now owns 2,409 shares of the company’s stock worth $186,000 after buying an additional 368 shares during the period. Lindbrook Capital LLC increased its stake in shares of Merck & Co., Inc. by 7.7% during the first quarter. Lindbrook Capital LLC now owns 5,567 shares of the company’s stock worth $429,000 after buying an additional 400 shares during the period. Finally, Legacy Financial Advisors Inc. increased its stake in shares of Merck & Co., Inc. by 31.7% during the first quarter. Legacy Financial Advisors Inc. now owns 10,922 shares of the company’s stock worth $842,000 after buying an additional 2,630 shares during the period. Institutional investors own 72.86% of the company’s stock.

A number of research firms recently weighed in on MRK. SVB Leerink cut their target price on shares of Merck & Co., Inc. from $103.00 to $102.00 and set an “outperform” rating on the stock in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Merck & Co., Inc. in a research note on Friday, February 5th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Merck & Co., Inc. has a consensus rating of “Buy” and a consensus price target of $97.22.

Merck & Co., Inc. stock traded up $0.10 during midday trading on Tuesday, reaching $76.08. 239,161 shares of the company were exchanged, compared to its average volume of 11,885,203. The company has a market capitalization of $192.51 billion, a price-to-earnings ratio of 16.81, a P/E/G ratio of 1.89 and a beta of 0.43. The firm’s 50-day simple moving average is $76.83 and its 200-day simple moving average is $78.38. Merck & Co., Inc. has a 1 year low of $71.71 and a 1 year high of $87.80. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.00 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 29th. The company reported $1.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.23). Merck & Co., Inc. had a return on equity of 53.83% and a net margin of 24.33%. The business had revenue of $12.08 billion during the quarter, compared to analyst estimates of $12.71 billion. During the same period in the previous year, the business posted $1.50 earnings per share. The firm’s quarterly revenue was up .2% on a year-over-year basis. On average, analysts forecast that Merck & Co., Inc. will post 5.9 EPS for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.

Featured Story: Understanding Market Liquidity

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.